Suresh Poda Ph.D

Suresh Poda, Ph.D has a diverse work experience in the field of neuroscience research and drug discovery. Suresh is currently serving as a Scientific Advisor at the Wyss Institute at Harvard University. Prior to that, they held the role of Vice President, Neuroscience and Preclinical Research at Encoded Therapeutics Inc.

From 2019 to 2021, Suresh was the Head of Biology at the Eisai Center for Genetics Guided Dementia Discovery (G2D2). Before that, they worked at Denali Therapeutics, where they served as a Senior Director and Director from 2015 to 2019.

Suresh Poda started their career at Lundbeck in 2004, where they held the positions of Associate Director and Senior Scientist. At Lundbeck, they contributed to the development of Xenazine, the first FDA-approved drug for Huntington's Chorea. Suresh also managed several hit finding projects and research staff in various areas of CNS therapeutic research.

Prior to joining Lundbeck, Suresh worked as a Scientist at AstraZeneca, where they focused on CNS Pain Target ID and validation.

Overall, Suresh Poda brings extensive expertise in neuroinflammation biology, target identification/validation, assay development, hit identification, lead optimization, and project leadership in the field of drug discovery for neurological disorders.

Suresh Poda Ph.D's education history is as follows:

Suresh Poda attended MIT Sloan School of Management, where they completed a Management Course. Suresh started their studies at an unknown date and finished in 2010.

Prior to their time at MIT, Suresh Poda was a Post Doctoral Fellow at the University of Michigan from 2000 to 2001.

Before that, they studied Receptor Pharmacology at Université de Montréal from 1997 to 2000.

No specific degree name was mentioned for their time at MIT Sloan School of Management and Université de Montréal.